Glaukos - GKOS Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GKOS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View GKOS analyst ratings or view top-rated stocks.

9 brokerages have issued twelve-month price objectives for Glaukos' shares. Their GKOS share price forecasts range from $48.00 to $69.00. On average, they expect the company's stock price to reach $60.13 in the next year. This suggests a possible upside of 29.6% from the stock's current price.
View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts.

Glaukos' stock was trading at $44.44 at the beginning of the year. Since then, GKOS shares have increased by 4.4% and is now trading at $46.41.
View the best growth stocks for 2022 here.

Glaukos saw a increase in short interest in October. As of October 15th, there was short interest totaling 4,160,000 shares, an increase of 5.3% from the September 30th total of 3,950,000 shares. Based on an average daily volume of 539,200 shares, the days-to-cover ratio is presently 7.7 days. Currently, 9.1% of the company's stock are short sold.
View Glaukos' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our GKOS earnings forecast.

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings data on Wednesday, November, 2nd. The medical instruments supplier reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.08. The medical instruments supplier had revenue of $71.27 million for the quarter, compared to analyst estimates of $67.88 million. Glaukos had a negative trailing twelve-month return on equity of 16.16% and a negative net margin of 31.45%.

Glaukos issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $278.00 million-$280.00 million, compared to the consensus revenue estimate of $278.63 million.

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.28%), Artisan Partners Limited Partnership (4.12%), State Street Corp (3.55%), Fred Alger Management LLC (2.94%), Lord Abbett & CO. LLC (2.40%) and Riverbridge Partners LLC (1.29%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends.

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GKOS stock can currently be purchased for approximately $46.41.

Glaukos (NYSE:GKOS) has a market capitalization of $2.21 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49,590,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

The company employs 727 workers across the globe.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.